In English
Enciclopedia de Salud

Health Condition


About This Condition

Angina, or angina pectoris, is chest pain due either to reduced blood flow to the heart or to certain other abnormalities of heart function.

Hardening (atherosclerosis) of the coronary arteries that feed the heart is usually the underlying problem. Spasms of the coronary arteries may also cause angina.

There are three main types of angina. The first is called stable angina. This type of chest pain comes on during exercise and is both common and predictable. Stable angina is most often associated with atherosclerosis. A second type, called variant angina, can occur at rest or during exercise. This type is primarily due to sudden coronary artery spasm, though atherosclerosis may also be a component. The third, most severe type is called unstable angina. This angina occurs with no predictability and can quickly lead to a heart attack. Anyone with significant, new chest pain or a worsening of previously mild angina must seek medical care immediately.

It is important for treatment and prevention of angina (and for overall health) to learn more about atherosclerosis


Common symptoms of angina include a squeezing pressure, heaviness, ache, or burning pain (like indigestion) in the chest that occur for 5 to 30 minutes at a time. These sensations are usually felt behind the breastbone but may also be felt in the jaw, neck, arms, back, or upper abdomen. Some people may also have difficulty in breathing or may become pale and sweaty. Symptoms of angina usually appear during physical exertion, after heavy meals, and with heightened emotional states, such as anger, frustration, shock, and excitement.

Other Therapies

Smoking is discouraged, since nicotine prevents proper blood flow. In advanced stages, surgical repair of the blood vessels in the heart may be recommended. Treatment may be directed toward underlying medical conditions, such as high cholesterol, high blood pressure, anemia, hyperthyroidism, obesity, or lung disease.


1. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247.

2. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993;71:S116-23 [review].

3. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo-controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569-72.

4. Canale C, Terrachini V, Biagini A, et al. Bicycle ergometer and echocardiographic study in healthy subjects and patients with angina pectoris after administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracing. Int J Clin Pharmacol Ther Toxicol 1988;26:221-4.

5. Cacciatore L, Cerio R, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: A controlled study. Drugs Exp Clin Res 1991;17:225-35.

6. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 1985;56:247.

7. Mortensen SA. Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone). Clin Investig 1993;71:S116-23 [review].

8. Mollace V, Romeo F, Martuscelli E, et al. Low formation of nitric oxide in polymorphonuclear cells in unstable angina pectoris. Am J Cardiol 1994;74:65-8.

9. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997;80:331-3.

10. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol 1999;83:1488-90.

11. Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996;94:130-4.

12. Saynor R, Verel D, Gillott T. The long-term effect of dietary supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and angina. Atherosclerosis 1984;50:3-10.

13. Mehta JL, Lopez LM, Lawson D, et al. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Effects on indices of platelet and neutrophil function and exercise performance. Am J Med 1988;84:45-52.

14. Wander RC, Du SH, Ketchum SO, Rowe KE. Alpha-tocopherol influences in vivo indices of lipid peroxidation in postmenopausal women given fish oil. J Nutr 1996;126:643-52.

15. Oostenbrug GS, Mensink RP, Hornstra G. A moderate in vivo vitamin E supplement counteracts the fish-oil-induced increase in in vitro oxidation of human low-density lipoproteins. Am J Clin Nutr 1993;57:827S.

16. Hanack T, Bruckel MH. The treatment of mild stable forms of angina pectoris using Crataegutt® novo. Therapiewoche 1983;33:4331-3 [in German].

17. Turlapaty P, Altura B. Magnesium deficiency produces spasms of coronary arteries: Relationship to etiology of sudden death ischemic heart disease. Science 1980;208:199-200.

18. Goto K, Yasue H, Okumura K, et al. Magnesium deficiency detected by intravenous loading test in variant angina pectoris. Am J Cardiol 1990;65:709-12.

19. Cohen L, Kitzes R. Magnesium sulfate in the treatment of variant angina. Magnesium 1984;3:46-9.

20. Cohen L, Kitzes R. Prompt termination and/or prevention of cold-pressor-stimulus-induced vasoconstriction of different vascular beds by magnesium sulfate in patients with Prinzmetal's angina. Magnesium 1986;5:144-9.

21. Shechter M, Bairey Merz CN, et al. Effects of oral magnesium therapy on exercise tolerance, exercise-induced chest pain, and quality of life in patients with coronary artery disease. Am J Cardiol 2003;91:517-21.

22. Marchetti G, Lodola E, Licciardello L, Colombo A. Use of N-acetylcysteine in the management of coronary artery diseases. Cardiologia 1999;44:633-7.

23. Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol 1997;29:941-7.

24. Pliml W, von Arnim T, Stablein A, et al. Effects of ribose on exercise-induced ischemia in stable coronary artery disease. Lancet 1992;340:507-10.

25. Riemersma RA, Wood DA, Macintyre CC, et al. Risk of angina pectoris and plasma concentrations of vitamins A, C, and E and carotene. Lancet 1991;337:1-5.

26. Rinzler SH, Bakst H, Benjamin ZH, et al. Failure of alpha-tocopherol to influence chest pain in patients with heart disease. Circulation 1950;1:288-90.

27. Rapola RM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA 1996;275:693-8.

28. Miwa K, Miyagi Y, Igawa A, et al. Vitamin E deficiency in variant angina. Circulation 1996;94:14-8.

29. Nieper H. Effect of bromelain on coronary heart diseases and angina pectoris. J Int Acad Prev Med 1976;3(2):62-3.

30. Heinicke R, van der Wal L, Yokoyama M. Effect of bromelain (Ananase) on human platelet aggregation. Experientia 1972;28:844-5.

31. Conn JJ, Kisane RW, Koons RA, Clark TE. Treatment of angina pectoris with khellin. Ann Intern Med 1952;36:1173-8.

32. Osher HL, Katz KH, Wagner DJ. Khellin in the treatment of angina pectoris. New Engl J Med 1951;244:315-21.

33. Ballegaard S, Pedersen F, Pietersen A, et al. Effects of acupuncture in moderate, stable angina pectoris: a controlled study. J Intern Med 1990;227:25-30.

34. Ballegaard S, Karpatschoff B, Holck JA, et al. Acupuncture in angina pectoris: do psychosocial and neurophysiological factors relate to the effect? Acupunct Electrother Res 1995;20:101-16.

35. Ballegaard S, Norrelund S, Smith DF. Cost-benefit of combined use of acupuncture, Shiatsu and lifestyle adjustment for treatment of patients with severe angina pectoris. Acupunct Electrother Res 1996;21:187-97.

36. Ballegaard S, Jensen G, Pedersen F, Nissen VH. Acupuncture in severe, stable angina pectoris: a randomized trial. Acta Med Scand 1986;220:307-13.

37. Richter A, Herlitz J, Hjalmarson A. Effect of acupuncture in patients with angina pectoris. Eur Heart J 1991;12:175-8.

38. Cunningham D, Brown S, Kaski JC. Effects of transcendental meditation on symptoms and electrocardiographic changes in patients with Cardiac Syndrome X. Am J of Cardiology 2000;85:653-5.

39. Burchett GC. Somatic manifestations of ischemic heart disease. Osteopathic Annals 1976;4:373-5.

40. Nicholas AS, DeBias, et al. A somatic component to myocardial infarction. Br Med J 1985;291:13-7.

41. Beal MC, Kleiber GE. Somatic dysfunction as a predictor of coronary artery disease. J Am Osteopath Assoc 1985; 85:70-5.

42. Beal MC Palpatory testing for somatic dysfunction in patients with cardiovascular disease. J Am Osteopath Assoc 1983;82:73-82.

43. Cox JM, Gorbis S, Dick LM, et al. Palpable musculoskeletal findings in coronary artery disease: results of a double blind study. J Am Osteopath Assoc 1983;82(11)832-6.

44. McGuiness J, Vicenzino B, Wright A. The influence of a cervical mobilization technique on respiratory and cardiovascular function. Man Ther 1997;2:216-20.

45. Vicenzino B, Cartwright T, Collins D. Cardiovascular and respiratory changes produced by lateral glide mobilization of the cervical spine Manual Therapy 1998;3(2):67-71.

46. Nansel D, Jansen R, Cremata E, et al. Effects of cervical adjustments on lateral-flexion passive end-range asymmetry and on blood pressure, heart rate and plasma catecholamine levels. J Manipulative Physiol Ther 1991;14:450-6.

47. LaCroix AZ, Mead LA, Liang KY, et al. Coffee consumption and the incidence of coronary heart disease. N Engl J Med 1986;315:977-82.

48. Deanfield J, Wright C, Krikler S, et al. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. N Engl J Med 1984;310:951-4.

49. Glantz SA, Parmley WW. Passive smoking and heart disease. JAMA 1995;273:1047-53 [review].

50. Todd IC, Ballantyne D. Antianginal efficacy of exercise training: A comparison with beta blockade. Br Heart J 1990;64:14-9.

Copyright © 2021 TraceGains, Inc. All rights reserved.

Learn more about TraceGains, the company.

The information presented by TraceGains is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires December 2021.

Copyright © 2021 TraceGains, Inc. Todos derechos reservados.

La información que se presenta en TraceGains no pretende nada más que informarle al consumidor con resultados interpretados de estudios científicos. A pesar de basarse en la investigación científica (humana, animal, o in vitro), en la experiencia clínica o en la observación de su aplicación en el uso tradicional, la información que se presenta en TraceGains y que se cita en cada artículo no pretende nada más que informarle al público. Además, es posible que no se logren los resultados presentados en todos los individuos. Enfermedades con peligro para la vida requieren tratamiento por prescripción facultativa y no se recomienda que intente curarlas sin que vigile un médico. Con respecto a muchas de las enfermedades discutidas, están disponibles medicamentos con y sin receta médica. Consúltese con su médico y/o farmacéutico para discutir cualquier problema de salud y siempre antes de utilizar cualquier suplemento o efectuar cualquier cambio con respecto a los medicamentos recetados que se toma. Esta información es válida hasta finales de Diciembre del 2021.